Renal Cell Carcinoma Clinical Trials
A listing of Renal Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 324 clinical trials
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration
- 144 views
- 22 Dec, 2020
- 1 location
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …
- 27 views
- 15 Sep, 2020
- 1 location
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a
- 0 views
- 23 Nov, 2020
- 3 locations
Alliance A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
- 186 views
- 08 Nov, 2020
- 1 location
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma
Subjects with Advanced Renal Cell Carcinoma
- 220 views
- 25 Mar, 2021
- 1 location
Procurement of Human Biospecimens for Research
Procurement of Human Biospecimens for Research
- 80 views
- 23 Nov, 2020
- 1 location
Procurement of Human Biospecimens for Research
Procurement of Human Biospecimens for Research
- 52 views
- 23 Nov, 2020
- 1 location
An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
An Open-Label, Dose-Escalation, Safety Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
- 80 views
- 08 Dec, 2020
- 7 locations
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …
- 128 views
- 14 Dec, 2020
- 4 locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear
- 2 views
- 05 Jun, 2021
- 78 locations